Edwards Lifesciences Acquires Embrella Cardiovascular, Inc.

IRVINE, CALIFORNIA – Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, announced that it has completed the acquisition of Embrella Cardiovascular, Inc., the developer of the Embrella Embolic Deflector System, which can be used during transcatheter heart valve procedures.

The purchase price was approximately $43 million cash, and the transaction closed today. Additionally, the company is maintaining its earnings guidance for the year.

“This acquisition is consistent with our dedication to the ongoing exploration and development of novel technologies that have the potential to improve outcomes for patients, and supports our strategy to extend Edwards’ global leadership in transcatheter heart valves,” said Larry L. Wood, Edwards’ corporate vice president, transcatheter valve replacement.

The single-use, disposable Embrella device is placed in the aorta through a sheath inserted in the right brachial or right radial artery. Its porous membrane allows blood flow to the brain while simultaneously deflecting embolic material. The Embrella Embolic Deflector System has been assessed in a limited clinical study in Europe and received CE Mark there in May 2010.

About Edwards Lifesciences

Edwards Lifesciences is the global leader in the science of heart valves and hemodynamic monitoring. Driven by a passion to help patients, the company partners with clinicians to develop innovative technologies in the areas of structural heart disease and critical care monitoring that enable them to save and enhance lives.